Suggested remit: To appraise the clinical and cost effectiveness of cladribine within its marketing authorisation for treating relapsing multiple sclerosis.
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6263

Provisional Schedule

Committee meeting: 1 13 November 2024
Expected publication 05 February 2025

Project Team

Project lead Vonda Murray

Email enquiries


Key events during the development of the guidance:

Date Update
22 April 2024 Invitation to participate
19 September 2023 - 17 October 2023 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6263
03 August 2023 In progress. DHSC referral received
03 March 2023 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual